| Product NDC: | 0029-4607 |
| Proprietary Name: | PAXIL |
| Non Proprietary Name: | paroxetine hydrochloride |
| Active Ingredient(s): | 25 mg/1 & nbsp; paroxetine hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0029-4607 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020936 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20100617 |
| Package NDC: | 0029-4607-13 |
| Package Description: | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0029-4607-13) |
| NDC Code | 0029-4607-13 |
| Proprietary Name | PAXIL |
| Package Description | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0029-4607-13) |
| Product NDC | 0029-4607 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | paroxetine hydrochloride |
| Dosage Form Name | TABLET, FILM COATED, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20100617 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | PAROXETINE HYDROCHLORIDE |
| Strength Number | 25 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Serotonin Reuptake Inhibitor [EPC],Serotonin Uptake Inhibitors [MoA] |